Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CLSD
$0.41
$
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Beta
1.787
Average Volume
Market Cap
Last Dividend
CIK
0001539029
ISIN
US1850632035
CUSIP
185063203
CEO
George Lasezkay
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
32
IPO Date
2016-06-02
Status
Inactive
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process | - Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - - IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema - ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. | GlobeNewsWire | 2025-11-24 07:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 15-12G | 2026-01-07 | 2026-01-07 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| EFFECT | 2025-12-16 | 2025-12-17 | View Filing |
| EFFECT | 2025-12-16 | 2025-12-17 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| POS AM | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| POS AM | 2025-12-15 | 2025-12-15 | View Filing |
| S-8 POS | 2025-12-15 | 2025-12-15 | View Filing |
| 8-K | 2025-12-08 | 2025-12-08 | View Filing |
| 25 | 2025-12-08 | 2025-12-08 | View Filing |
| 8-K | 2025-11-25 | 2025-11-25 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| 8-K | 2025-09-08 | 2025-09-08 | View Filing |
| 8-K | 2025-09-03 | 2025-09-03 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-08 | 2025-08-08 | View Filing |
| DEF 14A | 2025-08-04 | 2025-08-04 | View Filing |
| PRE 14A | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| S-8 | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| ARS | 2025-04-18 | 2025-04-18 | View Filing |
| DEFA14A | 2025-04-18 | 2025-04-18 | View Filing |
| DEF 14A | 2025-04-18 | 2025-04-18 | View Filing |
| PRE 14A | 2025-04-08 | 2025-04-08 | View Filing |
| SC 13G | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| SC 13G/A | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-24 | 2025-02-24 | View Filing |
| SC 13D/A | 2025-02-21 | 2025-02-21 | View Filing |
| 8-K | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2025-01-10 | 2025-01-10 | View Filing |
| 8-K | 2024-12-12 | 2024-12-12 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-11-04 | 2024-11-04 | View Filing |
| 8-K | 2024-10-09 | 2024-10-09 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-07-24 | 2024-07-24 | View Filing |
| 4 | 2024-06-24 | 2024-06-24 | View Filing |
| 3/A | 2024-06-24 | 2024-06-24 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 8-K | 2024-06-20 | 2024-06-20 | View Filing |
| 4 | 2024-05-15 | 2024-05-15 | View Filing |
| S-8 | 2024-05-10 | 2024-05-10 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| ARS | 2024-04-26 | 2024-04-26 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| 4 | 2024-04-19 | 2024-04-19 | View Filing |
| 4 | 2024-04-16 | 2024-04-16 | View Filing |
| 3 | 2024-04-16 | 2024-04-16 | View Filing |
| 8-K | 2024-04-16 | 2024-04-16 | View Filing |
| 4 | 2024-03-20 | 2024-03-20 | View Filing |
| 4 | 2024-03-18 | 2024-03-18 | View Filing |
| 3 | 2024-03-18 | 2024-03-18 | View Filing |
| 10-K | 2024-03-12 | 2024-03-12 | View Filing |
| 8-K | 2024-03-12 | 2024-03-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 20.75% | 1.01 | 229 | 0.03 | 0.05 | 76.08 |
| Choppiness Index Strategy | 13.38% | 1 | 387 | 0.02 | 0.03 | 68.7 |
| Donchian Channel Strategy | 10.90% | 0.99 | 69 | 0.04 | 0.09 | 66.22 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |